118 related articles for article (PubMed ID: 37977031)
1. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
3. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M; Dafni U; Gnant M; Polydoropoulou V; Hills M; Kiermaier A; de Azambuja E; Larsimont D; Rojo F; Viale G; Toi M; Harbeck N; Prichard KI; Gelber RD; Dinh P; Zardavas D; Leyland-Jones B; Piccart-Gebhart MJ; Dowsett M;
Clin Cancer Res; 2018 Jul; 24(13):3079-3086. PubMed ID: 29530933
[No Abstract] [Full Text] [Related]
4. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.
Tanioka M; Sakai K; Sudo T; Sakuma T; Kajimoto K; Hirokaga K; Takao S; Negoro S; Minami H; Nakagawa K; Nishio K
Breast Cancer Res Treat; 2014 Oct; 147(3):513-25. PubMed ID: 25200445
[TBL] [Abstract][Full Text] [Related]
6. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
8. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
[TBL] [Abstract][Full Text] [Related]
10. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
11. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.
Koo DH; Lee HJ; Ahn JH; Yoon DH; Kim SB; Gong G; Son BH; Ahn SH; Jung KH
Tumour Biol; 2015 Aug; 36(8):5865-71. PubMed ID: 25725586
[TBL] [Abstract][Full Text] [Related]
12. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.
Christodoulou C; Oikonomopoulos G; Koliou GA; Kostopoulos I; Kotoula V; Bobos M; Pentheroudakis G; Lazaridis G; Skondra M; Chrisafi S; Koutras A; Bafaloukos D; Razis E; Papadopoulou K; Papakostas P; Kalofonos HP; Pectasides D; Skarlos P; Kalogeras KT; Fountzilas G
Cancer Genomics Proteomics; 2018; 15(6):461-471. PubMed ID: 30343280
[TBL] [Abstract][Full Text] [Related]
14. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
Green AR; Barros FF; Abdel-Fatah TM; Moseley P; Nolan CC; Durham AC; Rakha EA; Chan S; Ellis IO
Breast Cancer Res Treat; 2014 May; 145(1):33-44. PubMed ID: 24706169
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
Okutur K; Bassulu N; Dalar L; Aydin K; Bozkurt M; Pilanci KN; Dogusoy GB; Tecimer C; Mandel NM; Demir G
Asian Pac J Cancer Prev; 2015; 16(7):2645-51. PubMed ID: 25854340
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
17. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
18. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
Feldt M; Bjarnadottir O; Kimbung S; Jirström K; Bendahl PO; Veerla S; Grabau D; Hedenfalk I; Borgquist S
J Transl Med; 2015 Apr; 13():133. PubMed ID: 25925673
[TBL] [Abstract][Full Text] [Related]
19. p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.
Pavlakis K; Bobos M; Batistatou A; Kotoula V; Eleftheraki AG; Stofas A; Timotheadou E; Pentheroudakis G; Psyrri A; Koutras A; Pectasides D; Papakostas P; Razis E; Christodoulou C; Kalogeras KT; Fountzilas G
Pathol Oncol Res; 2015 Apr; 21(2):273-82. PubMed ID: 25098276
[TBL] [Abstract][Full Text] [Related]
20. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]